Drug

Kelun Pharma's Sac-TMT Wins CDE Review Acceptance for Seventh Indication – First-Line Non-Squamous NSCLC Combo with MSD's KEYTRUDA
ADC / XDCKelun Pharmaceutical

Kelun Pharma’s Sac-TMT Wins CDE Review Acceptance for Seventh Indication – First-Line Non-Squamous NSCLC Combo with MSD’s KEYTRUDA

Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422) announced that a new indication application for sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) has been accepted for review by the Center for…

Joincare's LZSN2501 Cleared for Phase I Clinical Trials by NMPA – Dual-Epitope Bispecific Anti-FXI Antibody Targets VTE Prevention After Total Knee Arthroplasty

Joincare’s LZSN2501 Cleared for Phase I Clinical Trials by NMPA – Dual-Epitope Bispecific Anti-FXI Antibody Targets VTE Prevention After Total Knee Arthroplasty

Hengrui's Remimazolam Tosylate Wins China Approval for ICU Sedation During Mechanical Ventilation – Ruibeining Expands Into Critical Care

Hengrui’s Remimazolam Tosylate Wins China Approval for ICU Sedation During Mechanical Ventilation – Ruibeining Expands Into Critical Care

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
CARsgen's Satricabtagene Autoleucel Granted Priority Review by China's CDE
CancerCAR-T

CARsgen’s Satricabtagene Autoleucel Granted Priority Review by China’s CDE

Salubris Pharma's Xinchaotuo Gains NMPA Approval for Primary Hypertension
High blood pressureProduct approvals

Salubris Pharma’s Xinchaotuo Gains NMPA Approval for Primary Hypertension

Novartis' Beovu Approved by NMPA for Diabetic Macular Edema Treatment
NovartisNYSE: NVS

Novartis’ Beovu Approved by NMPA for Diabetic Macular Edema Treatment

Mabworks' MIL62 Gains NMPA Review for NMOSD Treatment
Mabworks BiotechMarket approval filings

Mabworks’ MIL62 Gains NMPA Review for NMOSD Treatment

Show More